AllianceBernstein’s Galectin Therapeutics GALT Stock Holding History

AllianceBernstein’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-12,400	Closed	-$27K	–	3356
2021 Q1	$27K	Hold	12,400	–	–	﹤0.01%	3211
2020 Q4	$28K	Sell	12,400 -1,600	-11%	-$4.2K	﹤0.01%	3155
2020 Q3	$37K	Sell	14,000 -1,900	-12%	-$5.32K	﹤0.01%	3133
2020 Q2	$49K	Buy	+15,900	New	+$40K	﹤0.01%	3161
2015 Q2	–	Sell	-2,000	Closed	-$7K	–	3106
2015 Q1	$7K	Sell	2,000 -200	-9%	-$714	﹤0.01%	3386
2014 Q4	$8K	Sell	2,200 -1,800	-45%	-$7.96K	﹤0.01%	3329
2014 Q3	$20K	Hold	4,000	–	–	﹤0.01%	3204
2014 Q2	$55K	Buy	4,000 +3,587	+869%	+$44.7K	﹤0.01%	3098
2014 Q1	$6K	Buy	413 +200	+94%	+$2.85K	﹤0.01%	3324
2013 Q4	$2K	Hold	213	–	–	﹤0.01%	3228
2013 Q3	$2K	Buy	+213	New	+$1.44K	﹤0.01%	3239

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein's GALT Position: Q2 2021 in Review

AllianceBernstein sold out of Galectin Therapeutics (GALT) in Q2 2021, closing a stake of 12,400 shares — an estimated $27K sold.

AllianceBernstein first reported a position in GALT in Q3 2013 and held it in 11 quarters. The position peaked at $55K in Q2 2014. 75 funds tracked by Wall St. Rank hold GALT as of Q2 2021.

AllianceBernstein reported no remaining Galectin Therapeutics position as of Q2 2021 after selling out during the quarter.
AllianceBernstein sold 12,400 Galectin Therapeutics shares in Q2 2021, an estimated $27K.
AllianceBernstein first reported a position in Galectin Therapeutics in Q3 2013 and held it in 11 quarters.
AllianceBernstein's Galectin Therapeutics position peaked at $55K in Q2 2014.
75 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2021.

Based on AllianceBernstein's 13F filing for Q2 2021, filed 30 Jul 2021.